Deals Of The Week: Amgen/Watson, Baxter/Momenta, Takeda/Intellikine
Executive Summary
Biosimilars took center stage during the last two weeks of 2011, as Amgen and Watson and then Baxter and Momenta followed up on the collaboration between Biogen Idec and Samsung BioLogics earlier in the month.
You may also be interested in...
Micro-Partnerships With Academia Helping To Drive Bristol’s Pipeline Development
New agreement with Duke Translational Medicine Institute highlights Bristol-Myers Squibb’s particular approach to collaborating with academia – small, low-money partnerships that get pharma and university scientists working together in an atmosphere virtually free of corporate bureaucracy.
Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.